Additionally, different molecular targets such as FMS-like tyrosine kinase 3 (FLT3), Nucleophosmin 1 (NPM1), CCAAT/enhancer binding protein alpha (CEBPA), cKIT and DNA methyltransferases 3A (DNMT3A) and leukemia-associated antigens, such as Preferentially Expressed Antigen in Melanoma (PRAME), Survivin, Receptor for Hyaluronic Acid Mediated Motility (RHAMM), G250, Synovial Sarcoma X breakpoint 2 Interacting Protein (SSX2IP) and Wilms’ Tumor 1 (WT1), offer new strategies. This evidence concerns the gene NPM1 and leukemia.